NCT03497897 - Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

February 24, 2022

Study Completion Date

March 9, 2022

Conditions

Inflammatory Acne

Interventions

DRUG

LYS006 20 mg

LYS006 20 mg, capsules, oral administration, BID, for 12 weeks

DRUG

LYS006 2 mg

LYS006 2 mg, capsules, oral administration, BID, for 12 weeks

DRUG

Placebo

Matching placebo, capsules, oral administration, BID, for 12 weeks

Trial Locations (17)

1085

Novartis Investigative Site, Budapest

6725

Novartis Investigative Site, Szeged

13353

Novartis Investigative Site, Berlin

33016

Novartis Investigative Site, Hialeah

48202

Novartis Investigative Site, Detroit

48455

Novartis Investigative Site, Bad Bentheim

53111

Novartis Investigative Site, Bonn

60590

Novartis Investigative Site, Frankfurt

70115

Novartis Investigative Site, New Orleans

77030

Novartis Investigative Site, Houston

78660

Novartis Investigative Site, Pflugerville

90404

Novartis Investigative Site, Santa Monica

95438

Novartis Investigative Site, Fremont

305 99

Novartis Investigative Site, Pilsen

06000

Novartis Investigative Site, Nice

06202

Novartis Investigative Site, Nice

6525EX

Novartis Investigative Site, Nijmegen